Axol Bioscience - June newsletter

This Month's Highlights

• June brought us?major advances?in the world of iPSCs and?in vitro?disease modelling, with the release of the ISSCR Standards Document paving the way for higher-quality research
• We also attended BIO International and ISSCR in Boston, engaging in discussions with passionate scientists and presenting our data on axoCells? iPSC-derived microglia
• On a personal note,?we heard from?our Head of Sales and Marketing, Duncan Borthwick, on his first 6 months at Axol and what he's learned so far from the world of human iPSCs

Axol and StrataStem announce collaboration on large-scale Alzheimer’s iPSC cohort?

We were delighted to announce our?exclusive agreement with StrataStem?which will enable us?to access and commercialize a large-scale collection of?iPSCs derived from StrataStem’s?Alzheimer’s Disease (AD) patient samples.

This signifies the first steps in building powerful?in vitro?Alzheimer’s models with a novel large cohort approach. Building powerful models at this scale will enable the creation of a ‘clinical-trial-in-a-dish’ platform, accessible for drug discovery companies to engage in drug development and patient stratification studies.

You can read the full press release here:?https://axolbio.com/axol-stratastem-announcement/?

Register for our LIVE webinar:?Powering multi-platform applications with axoCells? motor neurons

On Wednesday 28th June (4pm BST), we'll be running a webinar hosted by our R&D Team Leader, Stuart Prime.

Aside from access to Stuart's 20 years of industry experience, you can expect to hear about:

• The impressive data behind our motor neurons, including our industry-leading 10-day maturity times
• Our work developing complex NMJ assay models for human-relevant ALS drug discovery
• How we're powering a range of platforms with our axoCells motor neurons, including complex 2D and 3D models, multi-electrode array and microfluidic platforms

Don't miss out! Register your interest here:

https://events.teams.microsoft.com/event/4f08d7f2-c877-418e-aa48-60c3e67a2d3e@63407993-7ccd-4f6e-a4f8-1b8de8aa7594

| 4pm BST | 5pm CEST | 10am CDT | 11am EDT | 8am PDT |

New app note available to download: axoCells? atrial cardiomyocytes

Our?axoCells ventricular cardiomyocytes?are highly relevant,?CiPA-validated?and are available in just 7 days.

But if you're producing?atrial-specific models?(such as atrial fibrillation)?then you need high-quality, functionally relevant atrial cardiomyocytes.

We tested our axoCells atrial cardiomyocytes against our ventricular cells across a variety of parameters, including:

• Contractility waveforms
• Beat rate and duration with multiple pharmacological agents?

Our results demonstrated that our axoCells atrial cardiomyocytes exhibited distinct, functionally-relevant contractility responses measured on the FLEXcyte 96 platform.

You can access the full app note here:?https://axolbio.com/publications/contractility-assessment-of-axocells-atrial-cardiomyocytes-on-the-flexcyte-96-platform/

An invitation to microfluidics and organ-on-a-chip platform providers

From the FDA Modernization Act 2.0 to the recent ISSCR Standards Document, the drug discovery industry is becoming increasingly interested in advanced cell culture models like?microfluidics platforms and organ-on-a-chip devices. But powerful models need high-quality, relevant cells.

We'd like to invite platform providers to engage with us, with a view to collaborating on?industry-leading iPSC-based cell models.?We've specifically developed a library of high-quality iPSC-derived cells that can fuel microfluidics and organ-on-a-chip devices- just like we did with our?Netri collaboration.

If you're working in the microfluidics or organ-on-a-chip space,?get in touch?and let's explore how we can power your platforms with high-quality cells.

Get involved: our Looking To The Future program

Do you have 5 minutes to give your views on iPSC technology?

As part of our ‘Looking To The Future’ program, we’ve been?giving?iPSC researchers a platform?to share their views, needs and wants,?to inform our next steps in the world of?iPSC technology.?With rapid developments, new opportunities and growing interest in iPSC technology, we want to gather the thoughts of the scientists who use (or are planning on using) iPSCs for research and drug discovery.

If you'd like to give your thoughts, you can fill out our?questionnaire. It just takes 5 minutes and the data is confidential.

Whether you’re an avid iPSC user or have iPSCs at the tail end of your pipeline, we hope you will take part.

Here’s the link to have your say:

https://www.surveymonkey.co.uk/r/CFM6S2H